The headline numbers are striking. Between 1991 and 2024, the overall cancer death rate in the United States fell by 35 percent, an achievement the report attributes to reductions in smoking rates combined with advances in prevention, early detection, and treatment. That decline translates into 4.8 million fewer cancer deaths over the period. Survival gains are increasingly extending even to patients with advanced and metastatic disease: the five-year relative survival rate for distant-stage cancers of all types has more than doubled over the past three decades, rising from 17 percent in the mid-1990s to 36 percent during 2016 to 2022. Those figures, the report argues, are the direct product of sustained federal investment in the National Institutes of Health, the National Cancer Institute, the Food and Drug Administration, and the Centers for Disease Control and Prevention.

The regulatory pipeline tells a similar story of momentum. From July 1, 2025, to June 30, 2026, the FDA approved 11 new anticancer therapeutics, several of which marked historic firsts. Among them was the first molecularly targeted therapy for a rare, aggressive brain tumor driven by a specific genetic alteration, and the first approval of a proteolysis-targeting chimera, a novel class of drug that hijacks the cell’s own protein degradation machinery to destroy cancer cells, indicated for patients with breast cancer. The agency also greenlit the first immune checkpoint inhibitor for ovarian cancer and the first chimeric antigen receptor T-cell therapy for patients with marginal zone lymphoma, extending a living-drug approach once confined to a handful of blood cancers.

Beyond new molecules, the FDA expanded the uses of five previously approved anticancer therapeutics and cleared a series of devices and tools that signal where clinical care is heading. These included a wearable, noninvasive device for treating pancreatic cancer, an at-home human papillomavirus self-collection kit designed to widen access to cervical cancer screening, and several artificial intelligence-based tools intended to improve the early detection and diagnosis of cancers. Taken together, the approvals sketch a regulatory environment increasingly receptive to technologies that move diagnosis out of the clinic and into patients’ homes and that embed computational analysis into routine imaging and pathology.

Artificial intelligence features prominently in the report’s survey of new frontiers. Researchers have recently combined AI with advanced spatial imaging technologies to generate high-resolution maps of tumors, revealing how cancer and immune cells are organized and interact within the tumor microenvironment, knowledge that could guide the design of more effective immunotherapies. In drug development, one recently described AI model screened approximately 10,000 human proteins against more than 500 million compounds, identifying more than 2 million candidate molecules for further study, a scale of exploration unattainable through conventional laboratory screening alone. The report also notes that AI is improving the interpretation of routine medical images and the analysis of complex digital pathology slides, capabilities reflected in the recent FDA approvals of AI-assisted devices, and that AI-driven tools are helping clinicians predict outcomes, personalize treatment plans, and design better clinical trials, while potentially easing burnout among health care providers.

Cancer vaccines, long a tantalizing but elusive goal, are described as gaining real clinical traction. A small individualized pancreatic cancer vaccine trial has produced durable remissions in patients, including Donna Gustafson, one of several patients whose personal stories are woven through the report. In melanoma, patients with high-risk disease who received an individualized mRNA neoantigen vaccine alongside immunotherapy after surgery experienced sustained improvements in recurrence-free and distant metastasis-free survival compared with immunotherapy alone. For early-stage triple-negative breast cancer, an individualized mRNA vaccine generated durable neoantigen-specific T-cell responses, with most patients remaining relapse-free for up to six years after vaccination. A preventive strategy is also under exploration: an mRNA-based vaccine called Nous-209, designed to provoke immune responses against cells carrying Lynch syndrome-associated mutations, was found in a small trial to be safe, free of serious side effects, and capable of triggering a strong, durable immune response in people with the inherited condition.

The report also examines a question now hovering over primary care: whether the hugely popular GLP-1 weight loss drugs might reduce cancer risk. The evidence is genuinely mixed. One recent study found that semaglutide, sold as Ozempic and Wegovy, was associated with a 12 percent reduction in obesity-related cancer risk. A separate study of individuals with type 2 diabetes found that GLP-1 use was associated with a 40 percent lower risk of esophageal cancer and a 46 percent lower risk of colorectal cancer compared with insulin therapy, and other analyses suggest possible reductions in the risk of skin, breast, prostate, hematologic, and some gynecologic cancers. Yet a large review of 48 clinical trials involving more than 94,000 participants treated with GLP-1s found no significant reduction in the overall risk of obesity-related cancers, and some studies point in the opposite direction: liraglutide use was associated with a 70 percent increased risk of thyroid cancer and a 62 percent increased risk of respiratory cancer. The report’s verdict is cautious: the preventive role of these drugs, while promising, requires further investigation.

Against the progress, the report sets a sobering accounting of the disease’s continuing burden. In 2026, an estimated 2.1 million new cancer cases will be diagnosed in the United States, and more than 626,000 people will die from cancer. By 2050, annual new cases are projected to surpass 2.5 million, a 19 percent increase. Survival remains starkly unequal across tumor types: between 2016 and 2022, five-year relative survival was 13.7 percent for pancreatic cancer and just 6.6 percent for glioblastoma, an aggressive brain cancer, compared with 91.9 percent for female breast cancer and 98.2 percent for prostate cancer. The report also flags the rise of early-onset cancers, diagnosed in people aged 18 to 49, as a pressing public health concern. Globally, cancer incidence among people under 50 increased by nearly 80 percent between 1990 and 2019, with gastrointestinal cancers such as colorectal, stomach, and esophageal cancers contributing disproportionately. Researchers cite overlapping drivers including rising obesity, sedentary lifestyles, greater exposure to environmental pollutants, and shifts in dietary patterns.

The economic stakes are equally large. Direct costs of cancer care in the United States, many borne by patients themselves, were estimated at more than $236 billion in 2020, and one analysis cited in the report projects that cancer will cost the U.S. economy $5.3 trillion over the next three decades once indirect costs and lost productivity are included. It is against that backdrop that the AACR issues its policy demands. Most urgently, the organization calls on Congress to permanently block a proposed Office of Management and Budget rule, Regulation for Federal Financial Assistance, which the report warns would inject political considerations into funding decisions and broaden agencies’ authority to terminate grants for reasons unrelated to scientific merit. Bipartisan action has blocked the rule through December 11, 2026, but the report argues a temporary delay is not a lasting solution.

The Call to Action lays out specific asks: at least $51.303 billion for the NIH and at least $7.999 billion for the NCI in fiscal year 2027; protection of the cancer research workforce; preservation of scientific merit as the sole foundation of federal funding decisions; safeguards for active research awards and clinical trials; protection of researchers’ ability to publish and share findings; and risk-based, proportionate oversight of international collaboration. It further urges strengthening the FDA’s capacity to translate discoveries into patient benefits, sustaining evidence-based public health programs, modernizing interoperable data infrastructure, and removing barriers to prevention, screening, clinical trial participation, and survivorship care. AACR President Keith Flaherty, a physician-scientist who chaired the report’s steering committee, said advances in genomics, immunology, and artificial intelligence have given researchers more insight than ever into the complexities of cancer and are enabling treatments that precisely match each patient’s disease. Chief Executive Officer Margaret Foti added that decades of robust federal investment have transformed patient care and saved millions of lives, and that only by sustaining meritorious research free of political interference will the next generation of lifesaving breakthroughs emerge.

Subject of Research: Annual assessment of cancer research progress, FDA approvals, emerging technologies, and federal funding policy

Article Title: AACR releases annual cancer progress report highlighting promising advances for patients

Article References: AACR releases annual cancer progress report highlighting promising advances for patients. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: AACR, cancer progress report, FDA approvals, cancer mortality, immunotherapy, cancer vaccines, mRNA vaccines, artificial intelligence, GLP-1 receptor agonists, early-onset cancers, NIH funding, cancer screening